Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. ( SUPN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & CFO Conference Call Participants Peter Vozzo - Westwicke Partners, LLC Lin Tsai - Jefferies LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem - Piper Sandler & Co., Research Division Pavan Patel - BofA Securities, Research Division Stacy Ku - TD Cowen, Research Division Presentation Operator " Jack Khattar Founder, President, CEO, Secretary & Director " Timothy Dec Senior VP & CFO " Peter Vozzo Westwicke Partners, LLC " Lin Tsai Jefferies LLC, Research Division " Jefferies LLC, Research Division Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Research Division " Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem Piper Sandler & Co., Research Division " Piper Sandler & Co., Research Division Pavan Patel BofA Securities, Research Division " BofA Securities, Research Division Stacy Ku TD Cowen, Research Division " TD Cowen, Research Division Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $1.06 per share a year ago.
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Supernus Pharmaceuticals: Heading In The Right Direction
Supernus Pharmaceuticals shares have rallied nicely after strong 2Q25 results, driven by robust Qelbree and Gocovri sales and a surge in Zurzuvae revenue. Supernus' recent acquisition of Sage Therapeutics added Zurzuvae, the only FDA-approved oral postpartum depression drug, and bolstered the company's balance sheet. Management raised FY25 revenue guidance by 11% and expects continued growth, with analysts forecasting solid EPS and sales through FY27.
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.36 per share a year ago.
